Cooper Companies (NASDAQ:COO) Updates FY 2026 Earnings Guidance

Cooper Companies (NASDAQ:COO) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.510-4.550 for the period, compared to the consensus earnings per share estimate of 4.630. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.3 billion. Cooper Companies also updated its Q4 2026 guidance to 1.050-1.090 EPS.

Analysts Set New Price Targets

Several brokerages recently weighed in on COO. The Goldman Sachs Group set a $61.00 target price on Cooper Companies in a research note on Wednesday, May 27th. BNP Paribas Exane dropped their price target on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a research report on Monday, June 8th. Mizuho set a $85.00 price target on Cooper Companies and gave the stock an “outperform” rating in a report on Thursday, June 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Cooper Companies in a research report on Friday. Finally, Stifel Nicolaus dropped their target price on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cooper Companies has an average rating of “Hold” and an average target price of $81.64.

Cooper Companies Stock Performance

COO traded down $4.21 on Wednesday, hitting $63.48. 8,383,881 shares of the stock traded hands, compared to its average volume of 2,347,124. The business has a fifty day moving average price of $72.59 and a two-hundred day moving average price of $70.17. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $12.38 billion, a PE ratio of 53.80, a P/E/G ratio of 1.82 and a beta of 0.82. Cooper Companies has a 52 week low of $58.89 and a 52 week high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, research analysts predict that Cooper Companies will post 4.63 EPS for the current fiscal year.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Cresset Asset Management LLC raised its stake in shares of Cooper Companies by 7.5% in the 3rd quarter. Cresset Asset Management LLC now owns 4,393 shares of the medical device company’s stock valued at $301,000 after buying an additional 306 shares in the last quarter. Captrust Financial Advisors boosted its holdings in Cooper Companies by 10.0% during the second quarter. Captrust Financial Advisors now owns 3,500 shares of the medical device company’s stock valued at $249,000 after purchasing an additional 317 shares in the last quarter. Snowden Capital Advisors LLC lifted its position in shares of Cooper Companies by 10.0% during the 2nd quarter. Snowden Capital Advisors LLC now owns 4,088 shares of the medical device company’s stock worth $291,000 after buying an additional 373 shares during the period. Public Employees Retirement System of Ohio boosted its stake in Cooper Companies by 0.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 62,229 shares of the medical device company’s stock valued at $4,266,000 after buying an additional 386 shares in the last quarter. Finally, Arkadios Wealth Advisors grew its position in Cooper Companies by 14.3% in the fourth quarter. Arkadios Wealth Advisors now owns 3,552 shares of the medical device company’s stock valued at $291,000 after acquiring an additional 444 shares during the period. Institutional investors own 24.39% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.